VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2023 | NAPOLI-3: first-line NALIRIFOX in metastatic pancreatic ductal adenocarcinoma

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, presents findings from the Phase III NAPOLI-3 trial (NCT04083235), which compared liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX) to nab-paclitaxel with gemcitabine in previously untreated patients with metastatic pancreatic ductal adenocarcinoma. Patients receiving NALIRIFOX demonstrated superior overall survival and progression-free survival, providing a promising first-line treatment for a group of patients with limited options. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter